Featured Research

from universities, journals, and other organizations

Ritalin (Methylphenidate) Improves Attention, Behavior Of Children Surviving Leukemia, Brain Tumors

Date:
December 13, 2004
Source:
St. Jude Children's Research Hospital
Summary:
Children who suffer from behavioral and learning problems after their central nervous systems have been exposed to chemotherapy or radiation appear to benefit from treatment with methylphenidate (MPH), the drug commonly known by the brand name Ritalin.

Children who suffer from behavioral and learning problems after their central nervous systems have been exposed to chemotherapy or radiation appear to benefit from treatment with methylphenidate (MPH), the drug commonly known by the brand name Ritalinฎ. This finding, from investigators at St. Jude Children's Research Hospital, are published in the Dec. 1 issue of the Journal of Clinical Oncology (JCO).

The study suggests that MPH can at least temporarily reduce some of the attention and social deficits among survivors of childhood acute lymphoblastic leukemia (ALL) and brain tumors (BTs), the two most common forms of childhood cancer.

Previous studies have shown that these children are likely to develop significant cognitive and behavioral problems compared to their healthy peers, according to Raymond K. Mulhern, Ph.D., chief of St. Jude Behavioral Medicine. Mulhern is lead author of JCO report.

"Our three-week study gave us promising results for children suffering from attention and behavior problems due to their cancer treatments," Mulhern said. "Our future plans include follow-up evaluations of children who continue MPH treatment for three, six and 12 months. In addition to improvements in learning and behavior, we would also like to know if such treatment results in structural changes in the brain, as hypothesized by other researchers."

The St. Jude study is the first to examine the ability of two doses of MPH to reduce these problems at home and in the classroom among childhood cancer survivors.

The study included 83 long-term survivors, 40 of whom had survived ALL and 43 of whom survived BTs. The children (47 males and 36 females) were identified as having attention deficits as measured by specific tests and according to both parent and teacher reports. They ranged in age from six months to 14.3 years when they were first diagnosed with cancer, and 6.7 to 17.9 years when they were in the study.

The researchers identified specific children as having attention or behavior problems through various tests, such as the Wechsler scales (IQ tests) and Conner's Continuous Performance Test (selective and sustained attention, reaction time and level of impulsiveness). Each patient who agreed to participate was then randomly assigned to one of six sequences for a three-week course of treatment with MPH. Each sequence included a low dose of MPH (0.3 mg/kg of body weight), a moderate dose of MPH (0.6 mg/kg of body weight) and a placebo in one of the sequences (e.g., low dose, placebo, high dose). The drug and placebo were administered at school.

The effect of MPH on children in the study was measured by both teachers and parents, who used the Conners' Rating Scales, and teachers who used the Social Skills Rating System to assess the children. Both teachers and parents reported that, compared to placebo, MPH significantly improved the attention and behavioral problems, although the moderate dose was not consistently more effective than the low dose.

"The treatment of children with ALL and brain tumor shouldn't end after the cancer has been eradicated," said Wilburn E. Reddick, Ph.D., director of the diagnostic and signal processing laboratory at St. Jude and co-principal investigator. "This study has shown that follow-up therapy with MPH might help resolve some of the serious side-effects of cancer treatment."

Other authors of this paper are Raja B. Khan, Stuart Kaplan, Susan Helton, Robbin Christensen, Xiaoping Xiong and Sengjie Wu (St. Jude); Melanie Bonner and Sridharan Gururangan (Duke University, Durham, NC); and Ronald Brown (Temple University, Philadelphia, PA).

###

This work was supported in part by R01CA078957 from the National Cancer Institute, a Cancer Center Support (CORE) grant from the National Cancer Institute and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tennessee, St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.


Story Source:

The above story is based on materials provided by St. Jude Children's Research Hospital. Note: Materials may be edited for content and length.


Cite This Page:

St. Jude Children's Research Hospital. "Ritalin (Methylphenidate) Improves Attention, Behavior Of Children Surviving Leukemia, Brain Tumors." ScienceDaily. ScienceDaily, 13 December 2004. <www.sciencedaily.com/releases/2004/12/041203095411.htm>.
St. Jude Children's Research Hospital. (2004, December 13). Ritalin (Methylphenidate) Improves Attention, Behavior Of Children Surviving Leukemia, Brain Tumors. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/12/041203095411.htm
St. Jude Children's Research Hospital. "Ritalin (Methylphenidate) Improves Attention, Behavior Of Children Surviving Leukemia, Brain Tumors." ScienceDaily. www.sciencedaily.com/releases/2004/12/041203095411.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins